APM
IPSC icon

Avidity Partners Management’s Century Therapeutics IPSC Stock Holding History

Avidity Partners Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,221,555
Closed -$5.11M – 97
2024
Q1 		$5.11M Sell
1,221,555
-133,445
-10% -$565K 0.16% 76
2023
Q4 		$4.5M Buy
1,355,000
+256,500
+23% +$467K 0.16% 67
2023
Q3 		$2.2M Sell
1,098,500
-12,400
-1% -$33K 0.09% 81
2023
Q2 		$3.51M Sell
1,110,900
-157,200
-12% -$507K 0.12% 85
2023
Q1 		$4.4M Sell
1,268,100
-35,500
-3% -$156K 0.15% 73
2022
Q4 		$6.69M Hold
1,303,600
– – 0.14% 65
2022
Q3 		$12.9M Buy
1,303,600
+438,600
+51% +$4.62M 0.26% 65
2022
Q2 		$7.27M Hold
865,000
– – 0.17% 54
2022
Q1 		$10.9M Buy
865,000
+13,478
+2% +$179K 0.23% 60
2021
Q4 		$13.5M Buy
851,522
+112,253
+15% +$2.11M 0.29% 60
2021
Q3 		$18.6M Sell
739,269
-264,253
-26% -$7.15M 0.41% 56
2021
Q2 		$29.4M Buy
+1,003,522
New +$25.5M 0.8% 45

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Avidity Partners Management's IPSC Position: Q2 2024 in Review

Avidity Partners Management sold out of Century Therapeutics (IPSC) in Q2 2024, closing a stake of 1,221,555 shares — an estimated $5.11M sold.

Avidity Partners Management first reported a position in IPSC in Q2 2021 and held it in 12 quarters. The position peaked at $29.4M in Q2 2021. 61 funds tracked by Wall St. Rank hold IPSC as of Q2 2024.

  • Avidity Partners Management reported no remaining Century Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avidity Partners Management sold 1,221,555 Century Therapeutics shares in Q2 2024, an estimated $5.11M.
  • Avidity Partners Management first reported a position in Century Therapeutics in Q2 2021 and held it in 12 quarters.
  • Avidity Partners Management's Century Therapeutics position peaked at $29.4M in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2024.

Based on Avidity Partners Management's 13F filing for Q2 2024, filed 14 Aug 2024.